Tier 3 — preclinical
SIRT6 Deficiency Impairs Endothelial Integrity to Exacerbate Diabetic Atherosclerosis via Inhibiting Deacetylation-Dependent ZEB1 Degradation
Diabetes
2026
Online ahead of print, July 28 2026
Bibliography
- PubMed
- PMID 42519974
Study snapshot
| Design | Endothelial-cell-specific Sirt6 knockout and mechanistic diabetic atherosclerosis study. |
|---|---|
| Model | Diabetic atherosclerosis models and vascular endothelial cells. |
| Sample | Preclinical experimental cohorts. |
| Intervention | Endothelial Sirt6 deletion with pathway analysis; naringin used as a ZEB1-targeting intervention. |
| Duration | Disease-model experiments. |
| Endpoints | Atherosclerosis progression; Endothelial permeability; Monocyte/macrophage accumulation; ZEB1 acetylation/degradation; Claudin-1; Vascular barrier integrity |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified



